Novel perceptions and insights into the rare hematologic malignancy of acute megakaryocytic leukemia: a multicenter clinical retrospective study
AMKL is infrequent in clinical practice, features a poor prognosis, lacks specificity in clinical manifestations, and is prone to misdiagnosis or omission. Clinical trials of new drugs should be prioritized, while close monitoring of measurable residual disease (MRD) should be implemented. Patients with AMKL might benefit from induced remission chemotherapy combined with novel targeted therapy. Hematopoietic stem cell transplantation should be carried out as soon as possible after the first CR induced by standard chemotherapy to optimize the prognosis.
Authors
- Jiachen Xie (ORCID: https://orcid.org/0009-0001-6336-670X)
- Jianzhen Shen (ORCID: https://orcid.org/0009-0003-8586-267X)
- Yanquan Liu (ORCID: https://orcid.org/0000-0001-6826-0456)
- Yue Yin (ORCID: https://orcid.org/0000-0001-6210-0427)
- Zhengyuan Xu (ORCID: https://orcid.org/0000-0001-9075-8875)
- Xiaojun Chen (ORCID: https://orcid.org/0000-0002-8017-6844)
- Huidong Guo (ORCID: https://orcid.org/0009-0007-6914-4706)
- Huang He (ORCID: https://orcid.org/0000-0002-3885-6045)
Institutions
- Fujian Medical University (CN)
- Ganzhou People's Hospital (CN)
- First Affiliated Hospital of Gannan Medical University (CN)
- Union Hospital (CN)
- Putian University (CN)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-06-06
- DOI
- https://doi.org/10.3389/fmed.2025.1574132
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Health Commission of Jiangxi Province